Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

New Improved Drug Expected to Get FDA Approval Next Mont
May 23, 2022 (Investorideas.com Newswire) Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report.

H2/22 Slated to be Catalyst Rich for Pharma Co.
May 23, 2022 (Investorideas.com Newswire) Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that their newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.

Firm Reports Encouraging Trial Results in Cystinosis
May 20, 2022 (Investorideas.com Newswire) New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception.

Coverage Launched on Co. in Alzheimer's Drug Space
May 18, 2022 (Investorideas.com Newswire) This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action

Biotech Stock News: Thiogenesis (TSXV: TTI) Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
San Diego, California - May 18, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Thiogenesis Therapeutics, Corp. (TSXV: TTI) a clinical-stage biotechnology company developing sulfur-containing therapeutics for serious pediatric diseases, today announces positive results from its Phase 1 clinical study of oral TTI-0102 in healthy volunteers in Australia.

Biopharma Co. to Launch Two Clinical Trials This Year
May 16, 2022 (Investorideas.com Newswire) Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

Clinical Catalysts for Biotech's Stock On Track for Mid 2022
May 16, 2022 (Investorideas.com Newswire) Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

First Results From Biotech Co.'s Lymphoma Program Are Impressive
May 16, 2022 (Investorideas.com Newswire) This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.

Biotech Stock News: Nova Mentis (CSE: NOVA) Welcomes Autism Behaviour Analyst to its Science Team
Vancouver, British Columbia - May 12, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to welcome John Molinaro, a Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy, to its Scientific Advisory Board.

Biotech Stock News: NervGen Pharma (TSXV: NGEN) Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Vancouver, British Columbia - May 12, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today announced it has received approval from the Safety Review Committee to advance to the third and highest dose cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
Jackson Center, Pennsylvania--(Newsfile Corp. - May 24, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or cerebral spinal fluid (CSF), such as proteins, cytokines, amino acids, etc. Elimination of excessive quantities...

Nirvana Life Sciences Announces Partner Symeres Can Produce High Volume Controlled Substances
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products announces that its strategic partners Symeres are licensed to produce large quantities of controlled compounds required by Nirvana.The company is excited to announce that strategic partner Symeres has confirmed with Nirvana Life Sciences, its ability to produce up to...

Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th
Toronto, Ontario--(Newsfile Corp. - May 24, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that the company's CEO, Anthony Tennyson, will be attending The Investor Hotseat live stream event conducted by Psychedelic Invest. He will be joined in conversation with the host Dustin Robinson, Founder of...

Sona Provides Corporate Update

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021

Halifax, Nova Scotia--(Newsfile Corp. - May 19, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces the termination of its licensing agreement with Arlington Scientific for the Company's COVID-19 rapid saliva test following its analysis of data from two clinicial studies and consultations with the U.S. Food and Drug Administration ("FDA"). The studies included assessments of the test for both point-of-care ("POC") and for self-testing. The test achieved...

Hemostemix Announces Financing
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to 15 Million Units priced in the context of the market. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share...

Subscribe to Biotech News